Clinical trial
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or…
NCT00055809 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00055809 |
|---|---|
| Title | Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors |
| Official title | Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor |
| Intervention type | Biological, Other |
| Interventions | PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis |
| Enrollment | 44 |
| Start date | Jan 1, 2003 |
| Primary completion | Jun 1, 2007 |
| First posted | Mar 7, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: